Fadraciclib
Fadraciclib(Fadraciclib)
CAS: 1070790-89-4
化学式: C21H31N7O
| 中文名 | Fadraciclib |
| 英文名 | Fadraciclib |
| 别名 | 化合物CYC065 |
| 英文别名 | CDK259 CYC065 CYC-065 CPD1574 CYC-065 CYC 065 Fadraciclib CYC065 base 1070790-89-4 CYC065, CDK259 CYC065 free base 2-Pentanol, 3-[[6-[[(4,6-dimethyl-3-pyridinyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-, (2R,3S)- |
| CAS | 1070790-89-4 |
| 化学式 | C21H31N7O |
| 分子量 | 397.52 |
| 密度 | 1.25±0.1 g/cm3(Predicted) |
| 沸点 | 618.3±65.0 °C(Predicted) |
| 溶解度 | 溶于DMSO，不溶于水 |
| 酸度系数 | 14.62±0.20(Predicted) |
| 存储条件 | -20℃ |
| 产品用途 | Fadraciclib, also known as CYC065, is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities. CYC065 selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. |
| 参考资料 展开查看 | 1. Cocco E, et al. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016 Jul 26;115(3):303-11.2. Sumana Devata, et al. Molecular markers and venous thromboembolism (VTE) in acute myelogenous leukemia (AML) |
Fadraciclib - 配置溶液浓度参考
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.516 ml | 12.578 ml | 25.156 ml |
| 5 mM | 0.503 ml | 2.516 ml | 5.031 ml |
| 10 mM | 0.252 ml | 1.258 ml | 2.516 ml |
| 5 mM | 0.05 ml | 0.252 ml | 0.503 ml |
最后更新：2024-01-02 23:10:35
Fadraciclib - 细胞实验
Briefly, tumour cells are plated in six-well plates and treated with a titration of CYC065 concentrations (i.e., ranging from 100 to 500 nM). After 72 h, cells are harvested, washed and stained with propidium iodide (PI; 5 μg/mL) for flow cytometric counts. The percentage of viable cells is then normalized considering the vehicle-treated cells as 100% viable. Half-maximal inhibitory concentration values are determined using GraphPad Prism5 version 6. For drug combination studies, USC-ARK-1 and USC-ARK-2 cell lines are incubated with the combination of Taselisib and CYC065 at multiple paired concentrations including the IC50, the IC50/2 and the IC50*2 of each cell line to the corresponding drug (i.e., 10 nM of Taselisib and 198 nM of CYC065 for USC-ARK-1 and 50 nM of Taselisib and 62.5 nM of CYC065 for USC-ARK-2). Synergism is assessed by the combination index (CI). CI values <1 define a synergistic activity of the combination treatment. The CI values are calculated using the CompuSyn software .
最后更新：2023-08-16 21:32:38
Fadraciclib - 动物实验
Briefly, 5-7-week-old SCID mice are injected into the subcutaneous region with USC cells. A minimum of five animals per group are used. Treatments are administrated by oral gavage starting 1 week after tumor implantation when the size of the tumor is 0.125-0.150 cm3. Uterine serous carcinoma-ARK-2-derived xenografts are divided into two groups: one group of animal receive the vehicle, whereas the experimental group receives CYC065 (22.5 mg/kg daily for 3 weeks). Uterine serous carcinoma-ARK-1-derived xenografts are instead divided into four groups: one group receive the vehicle (0.5% methylcellulose-0.2% Tween-80), one group receive CYC065 (22.5 mg/kg daily for 3 weeks), one group receive Taselisib (10 mg/kg daily, 5 days per week per 3 weeks) and the last group receive the combination of CYC065 and Taselisib. The size of the tumor at the initiation of treatment is 0.125-0.150 cm3. Mouse weight and tumor size is recorded two times a week for the entire experimental period. Tumor volume is calculated.
最后更新：2023-08-16 21:32:38
供应商列表
提供多种规格现货供应
产品名: (2R,3S)-3-((6-(((4,6-二甲基吡啶-3-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)戊-2-醇 询盘CAS: 1070790-89-4
产地: 上海
包装: 25mg；250mg；100mg；50mg；10mg；1mg；1mL*10mM(inDMSO)；5mg；2mg；1mLx10mM(inDMSO)；200mg
规格: 98%；99.75%
价格: 电话、微信、QQ、邮件
库存: 现货
电话: 400-968-2212
手机: 18916960931
电子邮件: 3623107365@qq.com
QQ: 3623107365
微信: 18916960931
产品描述: (2R,3S)-3-((6-(((4,6-二甲基吡啶-3-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)戊-2-醇，98%；99.75%，Amole/ 更多
提供多种规格现货供应
产品名: Fadraciclib (Standard),1070790-89-4 去供应商网站查看 询盘CAS: 1070790-89-4
产地: 美国
包装: Inquiry
规格: HY-101212R
价格: 询价
库存: 期货
电话: 021-38924433; 021-58955995
手机: 18019480960
电子邮件: sales@medchemexpress.cn
现货供应
产品名: Fadraciclib 去供应商网站查看 询盘CAS: 1070790-89-4
产地: 上海
规格: ≥99%
价格: 5mg 2300,10mg 3500,25mg 7000,100mg 18000
库存: 现货
电话: 18301782025
手机: 18301782025
电子邮件: 3008007403@qq.com
QQ: 3008007403
微信: 18301782025
产品描述: Fadraciclib ≥99% MedMol 货号：T19547
提供多种规格现货供应
产品名: (2R,3S)-3-((6-(((4,6-二甲基吡啶-3-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)戊-2-醇 询盘CAS: 1070790-89-4
产地: 上海
包装: 25mg；250mg；100mg；50mg；10mg；1mg；1mL*10mM(inDMSO)；5mg；2mg；1mLx10mM(inDMSO)；200mg
规格: 98%；99.75%
价格: 电话、微信、QQ、邮件
库存: 现货
电话: 400-968-2212
手机: 18916960931
电子邮件: 3623107365@qq.com
QQ: 3623107365
微信: 18916960931
产品描述: (2R,3S)-3-((6-(((4,6-二甲基吡啶-3-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)戊-2-醇，98%；99.75%，Amole/ 更多
提供多种规格现货供应
产品名: Fadraciclib (Standard),1070790-89-4 去供应商网站查看 询盘CAS: 1070790-89-4
产地: 美国
包装: Inquiry
规格: HY-101212R
价格: 询价
库存: 期货
电话: 021-38924433; 021-58955995
手机: 18019480960
电子邮件: sales@medchemexpress.cn
现货供应
产品名: Fadraciclib 去供应商网站查看 询盘CAS: 1070790-89-4
产地: 上海
规格: ≥99%
价格: 5mg 2300,10mg 3500,25mg 7000,100mg 18000
库存: 现货
电话: 18301782025
手机: 18301782025
电子邮件: 3008007403@qq.com
QQ: 3008007403
微信: 18301782025
产品描述: Fadraciclib ≥99% MedMol 货号：T19547
您刚刚浏览过
你知道吗？
微信搜索化工百科或扫描下方二维码，添加化工百科小程序，随时随地查信息！